A NEW SCORECARD FOR OSTEOPOROSIS IN EU 27+2 REVEALS BURDEN OF DISEASE, GAPS, AND INEQUALITIES IN OSTEOPOROSIS & FRACTURE PREVENTION AND CARE

### BURDEN OF DISEASE

**100,000**

NEW FRAGILITY FRACTURES IN 2019

<table>
<thead>
<tr>
<th>FRACTURES</th>
<th>274</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>PER DAY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PER HOUR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**€1.1 BILLION**

SPENT IN 2019

HUGE COST BURDEN FOR OSTEOPOROSIS-RELATED HEALTHCARE

**€321.9 MILLION**

LONG-TERM DISABILITY COSTS

**€766.4 MILLION**

DIRECT COST OF INCIDENT FRACTURES

**€34.0 MILLION**

PHARMACOLOGICAL INTERVENTION

**+56%**

CHANGE IN COST PER INDIVIDUAL

**62.9€** 2010

**98.3€** 2019

**681,000**

INDIVIDUALS WITH OSTEOPOROSIS IN 2019

**79.1%**

WOMEN

**20.9%**

MEN

5.6% OF THE TOTAL POPULATION

**+23%**

PROJECTED INCREASE IN THE NUMBER OF FRAGILITY FRACTURES

**123,000** 2019

**100,000** 2034

### SERVICE PROVISION & UPTAKE

**61-98%**

REIMBURSEMENT OF OSTEOPOROSIS MEDICATIONS

**28.9**

AVAILABLE DXA UNITS/MILLION INHABITANTS

**€93**

DVA COST

**2144**

FRAX® SESSIONS/MILLION PEOPLE/YEAR

**N/A**

OF HOSPITALS HAVING FRACTURE LIASON SERVICES

YES

FRAX® RISK ASSESSMENT MODEL IS AVAILABLE

*NO DATA AVAILABLE*

**150,000**

WOMEN TREATED FOR OSTEOPOROSIS

**291,000**

WOMEN REMAIN UNTREATED FOR OSTEOPOROSIS

**441,000**

WOMEN ELIGIBLE FOR OSTEOPOROSIS TREATMENT

**66%**

TREATMENT GAP

### POLICY FRAMEWORK

**NO**

ESTABLISHED NATIONAL FRACTURE REGISTRIES

**NO**

OSTEOPOROSIS RECOGNISED AS A SPECIALTY

**YES**

OSTEOPOROSIS PRIMARILY MANAGED IN PRIMARY CARE

**OTHER SPECIALTIES INVOLVED IN OSTEOPOROSIS CARE**

**REHABILITATION**

### SCORECARD

<table>
<thead>
<tr>
<th>Domain</th>
<th>Belgium</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burden of Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fracture Risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifetime Risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRAX® Risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fracture Projections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service Provision</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Availability of DVA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Access to DVA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk Models</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guideline Quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liaison Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality Indicators</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NO DATA AVAILABLE*

The elements of each domain in each country were scored and coded using a traffic light system (red, orange, green) and used to synthesise a scorecard.